INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by infl ammation and fi brosis of the intra hepatic and extrahepatic bile ducts. Nearly 70 % of cases of PSC are associated with infl ammatory bowel disease, typically ulcerative colitis (UC). Patients with UC have an increased risk for developing colorectal cancer and dysplasia ( 1, 2 ) . Individuals with concomitant PSC and UC are at a higher risk of developing colorectal cancer than in patients with UC alone ( 3 ) .
Ursodeoxycholic acid (UDCA) is a synthetic bile acid that is the 7-β -epimer of chenodeoxycholic acid (CDCA). It has been used frequently for therapy in PSC without clear evidence of improved outcomes, though it has been shown to improve liver biochemistries ( 4 -7 ) . Using the Mayo risk score as an end point, a pilot study using 25 -30 mg / kg / day of UDCA suggested that such a dose could improve survival ( 7 ) . Th is prompted a multicenter, placebo-controlled trial that investigated the use of UDCA 28 -30 mg / kg / day in patients with PSC. Th is study revealed an improvement in liver biochemistries but no improvement in survival and a higher rate in adverse events in the UDCA group. A preliminary analysis reported from this study did not reveal any eff ect on the development of colonic dysplasia in the initial cohort, including those who did not have UC ( 4 ) .
Animal and in vitro studies have also suggested that UDCA may have a role as a chemopreventive agent in the prevention of colorectal neoplasia ( 8 -12 ) . Multiple human studies also have investigated the role of UDCA as a chemopreventive agent, and results Some studies have suggested that ursodeoxycholic acid (UDCA) may have a chemopreventive effect on the development of colorectal neoplasia in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). We examined the effects of high-dose (28 -30 mg / kg / day) UDCA on the development of colorectal neoplasia in patients with UC and PSC.
High

METHODS:
Patients with UC and PSC enrolled in a prior, multicenter randomized placebo-controlled trial of highdose UDCA were evaluated for the development of colorectal neoplasia. Patients with UC and PSC who received UDCA were compared with those who received placebo. We reviewed the pathology and colonoscopy reports for the development of low-grade or high-grade dysplasia or colorectal cancer.
RESULTS:
Fifty-six subjects were followed for a total of 235 patient years. Baseline characteristics (including duration of PSC and UC, medications, patient age, family history of colorectal cancer, and smoking status) were similar for both the groups. Patients who received high-dose UDCA had a signifi cantly higher risk of developing colorectal neoplasia (dysplasia and cancer) during the study compared with those who received placebo (hazard ratio: 4.44, 95 % confi dence interval: 1.30 -20.10, P = 0.02).
are confl icting. Two clinical studies suggested that UDCA reduced the incidence of colorectal neoplasia in patients with UC and PSC ( 13, 14 ) ; however, a third study indicated that the development of cancer and dysplasia was the same regardless of whether they received UDCA ( 15 ) . Consequently, it is not clear in clinical practice whether or not patients with PSC and UC should be started on UDCA for the prevention of colonic neoplasia. Because of the limited information, the American Association for the Study of Liver Diseases recommends against the use of UDCA for the chemoprevention of colorectal cancer in patients with PSC and UC ( 16 ) . High-dose UDCA has recently been studied as a treatment for PSC ( 4 ) , and it is not clear whether higher-dose UDCA would have better chemopreventive properties than lower-dose UDCA. Th is uncertainty prompted us to conduct a retrospective review of a randomized-controlled trial in patients with PSC and UC, to determine the safety and preventive eff ect of high-dose UDCA on the development of colorectal neoplasia when compared with placebo.
METHODS
We conducted a nested cohort study using data collected during a randomized, double-blind, placebo-controlled multicenter trial of high-dose UDCA (28 -30 mg / kg / day). Detailed information on the study design and the main results of this study have been recently published ( 4 ) . Th is follow-up study was approved by the Mayo Clinic Institutional Review Board and the initial study was approved by the institutional review boards at each site.
Inclusion criteria
Th e diagnosis of PSC was based on the following criteria: (i) chronic cholestatic disease for at least 6 months; (ii) serum alkaline phosphatase at least 1.5 times the upper limits of normal; (iii) retrograde, operative, magnetic resonance, or percutaneous cholangiography, revealing intrahepatic and / or extrahepatic biliary duct obstruction, beading, or narrowing within 1 year of study entry; and (iv) liver biopsy within the past year that was available for review and compatible with PSC. Th e diagnosis of UC was made by the typical clinical, endoscopic, and histologic criteria ( 17 ) and only those patients with a diagnosis of UC at the time of study entry were included.
Exclusion criteria
Patients were excluded in the following circumstances: (i) colectomy before study entry; (ii) prior history of colorectal dysplasia or cancer; (iii) comorbidities that would limit life expectancy to < 2 years; (iv) inability to give consent; (v) treatment with UDCA, pentoxifylline, corticosteroids, cyclosporin, colchicine, azathioprine, methotrexate, D -penicillamine, budesonide, nicotine, pirfenidone, or tacrolimus in the 3 months before study entry; (vi) if they did not undergo a screening colonoscopy aft er randomization; (vii) if they had received therapy for UC in the past 3 months other than maintenance therapy with 5-ASA compounds (individuals on non-5-ASA therapies before the trial were not asked to stop such medications, rather they were not enrolled into the study); (viii) end-stage liver disease determined by clinical or laboratory parameters with or without an anticipated need for a liver transplant within the next 2 years; (ix) pregnancy or lactation; (x) age < 18 years or > 75 years; (xi) prior intraductal stones or biliary operations other than cholecystectomy; (xii) presence of other chronic liver disease; and (xiii) recurrent cholangitis requiring hospitalization more than two times per year.
Randomization and study drug
All eligible patients were randomized by computer to study drug or placebo stratifi ed by histologic stage of PSC, Mayo risk score, and presence of varices. Patients received UDCA 28 -30 mg / kg / day (Axcan Pharma, Mont-St Hilare, Canada) or an identical placebo in divided doses given with meals and a bedtime snack. In July 2008, participants were asked to stop taking the study drug or placebo secondary to an increase in adverse events in the UDCA group.
Data abstraction
Th e data were abstracted on a standardized template. Th e database from the previous UDCA trial and clinical records, when available, were reviewed to obtain patient demographics, date of randomization and event (neoplasia, liver transplant, colectomy, death), age at diagnosis of PSC, duration of PSC and histologic stage (I -IV) at study entry, duration of UC, severity of UC, colonoscopy and pathology reports, smoking status, family history of colorectal cancer, medication use, presence of pancolitis, and the number of surveillance biopsies per colonoscopy. Th e study protocol included colonoscopy and surveillance biopsies within 1 year of entry and annually thereaft er in individuals with colitis. If colorectal neoplasia was present on the colonoscopy within 1 year of entry or at another time point before the study, they were excluded. During the initial study, if colorectal neoplasia was detected, study personnel entered this into standard abstraction and adverse event forms. If colonoscopies were available at other time points, they were included in our review. For example, the initial prospective high-dose UDCA trial ended in July 2008. Participants were then asked to continue ongoing surveillance per the initial protocol, which included surveillance colonoscopies with biopsies. Th e number of surveillance biopsies was determined per institutional protocol. Patients who did not undergo a surveillance colonoscopy aft er randomization were excluded.
Pathology, colonoscopy, and adverse event reports were examined to identify cases of colorectal neoplasia. Cases of colorectal neoplasia were determined by expert gastrointestinal pathologists at each study site who were blinded to the treatment group. Th e standard grading and classifi cation of dysplasia was applied, except lesions interpreted as indefi nite for dysplasia were not subdivided into categories of probably positive or negative ( 18 ) . Indefi nite lesions were not included as an end point. All cases were reviewed by two coauthors and adjudicated. All cases of colorectal neoplasia were included in the primary analysis. In the secondary analysis, cases of dysplasia were excluded if they may have occurred in an adenoma-like lesion ( 19, 20 ) .
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We also reviewed data regarding serum bile acid composition in these patients, when available, before and aft er treatment with high-dose UDCA. Serum samples were taken at entry to the study and at the end of treatment with UDCA. We determined the change in lithocholic acid (LCA), deoxycholic acid (DCA), UDCA, CDCA, CA (cholic acid), and total bile acid levels before and aft er treatment. More details on the changes in bile composition from the original study have been previously published ( 21 ) .
Statistical analysis
Continuous data were expressed as the mean ± s.d. or medians and ranges. Categorical data were expressed as the number of subjects (and percentage). Diff erences in continuous variables between the study groups were assessed using two-sided t -tests and non-parametric Wilcoxon tests. Follow-up was calculated from the time of enrollment to the time of an end point (neoplasia) or censoring event (death, liver transplant, or colectomy), whichever was earliest, and if neither occurred then the last colonoscopy with biopsy. Comparison of categorical data between the study groups was performed using χ 2 or Fisher ' s exact method where appropriate. Overall survival free of neoplasia curves were plotted for the groups of interest using the Kaplan -Meier method. Multivariate analysis was performed using a Cox-proportional hazard regression, with P ≤ 0.10 in univariate analysis required for entry into the model. All tests were two-sided, and the chosen level of significance was P < 0.05. Analysis was performed using JMP soft ware (version 8.0; SAS Institute, Cary, NC).
RESULTS
We identifi ed 91 patients with PSC and concomitant UC at the time of enrollment into the original study. For the purposes of this study, 35 patients were excluded: 26 had a colectomy or prior history of colorectal neoplasia before enrollment and 9 patients did not undergo a colonoscopy aft er randomization. Th erefore, 65 patients could have been eligible but 9 (14 % ) were excluded due to the lack of a colonoscopy. Of the 56 subjects included in our study, 25 were randomized to UDCA and 31 to placebo. Of the eight cases of dysplasia reported in the initial high-dose UDCA trial ( 4 ), four individuals (placebo) were excluded secondary having Crohn ' s disease or a prior history of colorectal neoplasia. Table 1 summarizes the patient characteristics. Th e duration of follow-up was 235 patient years, with a mean duration of follow-up and drug use of 4.0 ± 1.54 years in the UDCA group and 4.35 ± 2.02 years in placebo group ( P = 0.48). During follow-up, the number of surveillance colonoscopies in both groups was similar (median, 4, range 1 -8, in the UDCA group vs. 4, 1 -7, in the placebo group). Th e time between colonoscopies aft er randomization was also similar (median, 377 days, range 98 -1,482 days, in the UDCA group vs. 389 days, 21 -1,386 days, in the placebo group). Endoscopic surveillance was balanced between the two groups and further adjustments were not made. Aft er the initial trial was stopped, participants were asked to continue the same surveillance in a prospective follow-up study. Th is included annual colonoscopies with surveillance biopsies. Eleven (four UDCA, seven placebo) out of 37 people who would have been eligible for ongoing surveillance (did not reach an end point or were censored previously) did not consent for ongoing participation or were lost to follow-up aft er the initial high-dose UDCA trial was stopped in July 2008. Th e proportion of those who did not have ongoing surveillance colonoscopies was similar between groups (UDCA 4 / 12 (33 % ); placebo 7 / 25 (28 % )). Th e remaining 26 (70 % ) people (8 UDCA and 18 placebo) had at least one colonoscopy with biopsies aft er the initial study ended that was reviewed. No new cases of colorectal neoplasia were detected in these 26 individuals aft er cessation of the initial study.
In our primary analysis, a total of 12 patients developed colorectal neoplasia during follow-up. Nine patients had received highdose UDCA (one colon cancer, one high-grade dysplasia, and seven low-grade dysplasia), and three patients had received placebo (one colon cancer, one high-grade dysplasia, and one low-grade dysplasia). Eleven of the 12 cases of neoplasia occurred during the initial high-dose UDCA trial. One new case of dysplasia was detected 4 months aft er cessation of high-dose UDCA. Th is patient ultimately underwent a colectomy for an unresectable lesion. Of the nine patients in the UDCA group with colorectal neoplasia, six had lesions proximal to the splenic fl exure. In the three patients who received placebo, one patient had two low-grade lesions (one proximal and one distal to the splenic fl exure). For the remaining two patients, one had a lesion proximal to the splenic fl exure and the other patient had a lesion distal to the splenic fl exure. In the UDCA group, the majority (78 % ) of patients developed colorectal neoplasia aft er 2 years of use. Survival free of dysplasia is illustrated in Figure 1 . Th e use of high-dose UDCA was associated with a higher incidence of colorectal neoplasia compared with placebo (hazard ratio (HR): 4.44, 95 % confi dence interval (CI): 1.30 -20.10, P = 0.02).
Six individuals eventually underwent a liver transplant (four in the UDCA group and two in placebo group). Of those six, only one (assigned to UDCA group) developed colorectal neoplasia and the transplant occurred aft er they reached our primary end point. One patient in the placebo group died of liver failure aft er they reached an end point. One person in the UDCA group died secondary to a gastrointestinal hemorrhage. Aft er randomization, seven had a colectomy (four in UDCA and three in placebo group). In the UDCA group, all four individuals with a colectomy had a history of colorectal neoplasia and two of the three people in the placebo group who received a colectomy had a history of dysplasia or colon cancer. Of the fi ve people with dysplasia in the UDCA group who did not undergo a colectomy, four had recurrent or persistent dysplasia detected on subsequent colonoscopies while they were still taking high-dose UDCA. Four of those fi ve individuals had at least one colonoscopy aft er cessation of high-dose UDCA. Aft er highdose UDCA was stopped, three of those four patients did not have dysplasia detected on a subsequent colonoscopy.
We evaluated the association of multiple covariates with the development of colorectal neoplasia using univariate analyses and Cox-proportional hazards regression, as shown in Table 2 . In univariate analysis, only smoking history and UC duration met our threshold for inclusion in the multivariate analysis. Aft er adjusting LIVER High-Dose UDCA Associated With Colorectal Neoplasia for smoking, and UC duration, the use of high-dose UDCA was still associated with a higher incidence (HR: 5.97, 95 % CI: 1.39 -41.44, P = 0.02) of colorectal neoplasia.
Serum bile composition before and aft er treatment was available for review in 14 patients who received high-dose UDCA. Of those, four developed colorectal neoplasia and the other 10 did not. Th e change in bile acid composition between those who did and did not develop colorectal neoplasia was not statistically signifi cant ( Table 3 ). However, there was a trend toward a greater increase in LCA (0.6 ± 0.6 vs. 0.2 ± 0.2, P = 0.28) and CDCA (0.6 ± 0.8 vs. 0.1 ± 0.3, P = 0.22) in those who developed colorectal neoplasia compared with those who did not.
In a secondary analysis, four patients with a lesion possibly consistent with an adenoma-like dysplastic lesion were censored at the time of liver transplant, death, or last colonoscopy with biopsy, but not counted as having reached a dysplasia end point. Of the remaining eight patients, six received UDCA and two received placebo. Th e use of high-dose UDCA trended toward an increase in colorectal neoplasia in this analysis, although this diff erence was not statistically signifi cant (HR: 4.00, 95 % CI: 0.92 -27.39, P = 0.07). Multivariate analysis was not performed aft er excluding these four cases, as none of the covariates met our threshold for inclusion. history and UC duration. Other important covariates such as age at study entry were not associated with the development of colorectal neoplasia. Th e majority of patients developed colorectal neoplasia aft er ≥ 2 years of UDCA use. Aft er excluding lesions possibly consistent with an adenoma ( 19, 20 ) , the HR for the association with colorectal neoplasia did not change signifi cantly, but due to the small number of cases, the CI for this association was wide, and the use of high-dose UDCA was not associated with a statistically signifi cant risk of colorectal neoplasia. Our results are in contrast with several prior studies. In vitro and animal studies suggested that UDCA may have a role as a chemopreventive agent. Several mechanisms for which UDCA may act to prevent colorectal cancer have been proposed, including downregulation of cyclooxygenase-2 expression, prevention of carcinogen-induced changes in protein c, inhibiting cell proliferation by suppressing epidermal growth factor receptor, which is typically activated by DCA, and altering the bile acid milieu to reduce secondary bile acid levels ( 8 -12 ) . Lower doses of UDCA may have a protective role as it may have an antiapoptotic eff ect. For example, exposing human colon cancer cell lines to UDCA can decrease DCA-induced apoptosis ( 22 ) .
Th ere is limited data regarding the role of UDCA in colorectal neoplasia prevention in PSC patients with UC. Two studies have
DISCUSSION
Our study revealed that high-dose UDCA administration in patients with PSC and UC was associated with a higher rate of colorectal neoplasia compared with placebo. Th is association remained statistically signifi cant aft er adjusting for smoking Although the mean duration of UDCA was similar to our study, our dose was nearly three times higher.
Our group performed a previous study that examined a lower dose of UDCA at 13 -15 mg / kg / day. Th e present study and the one conducted by Pardi et al. ( 14 ) were similar in that they are both retrospective reviews of randomized-controlled trials. In addition, the proportion of patients that could have been appropriate for inclusion but had to be excluded were also similar. With the exception for censoring at the time of transplant, both studies had similar censoring events. In contrast to the primary analysis presented in this study, Pardi et al. excluded cases of dysplasia occurring in a typical adenoma for the primary end point aft er confi rmation of dysplasia by a single blinded pathologist and found that a relative risk for developing dysplasia was 0.26 (95 % CI: 0.06 -0.92). However, when we excluded cases of dysplasia that may have occurred in a typical adenoma, the HR for the increased risk did not change signifi cantly, although the association no longer reached statistical signifi cance. Th erefore, it is unlikely that methodologic diff erences between the studies would be suffi cient enough to explain the differing results. Another distinction is that the initial study reviewed by Pardi et al. did not exclude patients on therapy with non-5-ASA compounds within 3 months before enrollment. Th is is in contrast with the present study and that may have been selected for a diff erent population of UC patients despite a small proportion of these individuals requiring the initiation of non-5-ASA agents aft er enrollment. Furthermore, individuals in the present study tended to have more intensive endoscopic surveillance in terms of the median number of colonoscopies, less time between colonoscopies, and number of surveillance biopsies. Th ough the duration of UC and follow-up time were longer compared with the current study, the duration of UDCA use was slightly shorter in that study. In the present study, the duration of PSC was shorter and we had fewer men. In addition, the age in the UDCA group was older.
Wolf et al. ( 15 ) conducted a retrospective cohort study over 120 patients (92 controls and 28 cases) over a median period of 21 and 22 years for the UDCA and control groups, respectively. Th e mean duration of UDCA use was 3.4 years, which is slightly less than our study. Th is study did not fi nd a reduction in colorectal cancer or dysplasia in the UDCA group nor did they fi nd that increasing the dose provided any benefi t. It is unclear what the mean dose was but it is unlikely that they utilized doses as high as 28 -30 mg / kg / day. Moreover, it may be possible that this study was underpowered.
It has been postulated that bile acids may have a role in colon carcinogenesis, particularly the secondary bile acids (LCA and DCA) ( 23 -25 ) . In vitro studies have suggested that certain bile acids can induce DNA damage. For example, LCA has been shown to cause DNA damage in colonic cells ( 26, 27 ) . In addition, hydrophobic bile acids may induce oxidative stress in gastrointestinal cancer cells ( 28 ) . Th erefore, it has been suggested that bile acids may have a role in gastrointestinal cancers via a prolonged exposure to high bile acid concentrations leading to oxidative stress, selection for cells resistant to apoptosis, and replication with unrepaired DNA damage ( 25, 29 ) . Th us, one possible biologic mechanism behind our surprising results could be an increase in supraphysiologic levels of hydrophobic bile acids aft er a prolonged exposure to high doses of UDCA. A potential reason why this eff ect has not been observed in lower doses of UDCA is high-dose UDCA (28 -30 mg / kg / day) has resulted greater increases in the serum UDCA levels than at lower doses ( 21 ) . We reported that there was a statistically signifi cant increase in the serum UDCA and LCA levels in the treatment group compared with placebo and an expansion of the total serum bile acid pool without signifi cant changes in CA, DCA, or CDCA levels ( 21 ) . It is unknown if prolonged exposure to high-dose UDCA leads to increased colonic levels of LCA, DCA, or other toxic bile acids in our cohort as such samples were not collected in the initial study. However, absorption of UDCA is incomplete ( 30, 31 ) . Consequently, it would be expected that a proportion of the UDCA would be metabolized by bacterial fl ora to other bile acids. UDCA can be metabolized to both LCA and CDCA by intestinal fl ora ( 32 ) . CDCA is typically metabolized to LCA by bacterial fl ora. Both CDCA and LCA have been shown to stimulate in vitro cell invasion in a dose-dependent 
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